31 May 2024 • Plasma ACE2 (angiotensin-converting enzyme 2) may be used as a marker for determining the prognosis of diabetic kidney disease, discloses a 9-year U-CARE study.

Diabetic kidney disease is the most common complication of diabetes and its early detection, risk assessment, and treatment remain a difficulty. Identification of new biomarkers is essential.

In the urinary biomarker for continuous and rapid development of diabetic nephropathy study (U-CARE) that enrolled 777 participants with diabetes, 296 were followed up for 9 years and their plasma and urine ACE2 levels were tested with the ELISA method.

According to the study, greater baseline plasma ACE2 levels in diabetic patients were protective against the development and progression of albuminuria and were related to fewer renal endpoints.

Source: BMJ | Read full story